abstract |
The present invention provides a tenascin-3 FnIII domain-based multimeric scaffold that specifically binds to TRAIL receptor 2 (TRAIL R2), a cell membrane receptor involved in apoptosis. The invention further provides engineered variants with increased affinity for the target, increased stability, and reduced immunogenicity. Furthermore, the present invention relates to engineered multivalent scaffolds as prophylactic, diagnostic or therapeutic agents and their use against diseases caused by cells expressing TRAIL R2, in particular for therapeutic use against cancer. . [Selection figure] None |